Claris Ventures — Full Portfolio
11 tracked investments · listed companies and verified rows first
Lever Bio develops immunotherapy drug candidates in immuno-oncology, partnering with top researchers and academic institutions to translate discoveries into cancer immunotherapies.
BiotechDeep TechHealthtechMedical Devices
Pietro Puglisi(Chief Executive Officer)in
Co-investorsExor VenturesItalian Angels for GrowthClub degli InvestitoriOra Global
ALKemist Bio develops immunotherapies targeting the ALK oncogene in cancer by engineering autologous T cells with synthetic receptors to recognize and eliminate ALK-positive tumor cells.
BiotechDigital HealthMedical Devices
Roberto Chiarle
Co-investorsClub degli InvestitoriItalian Angels for GrowthLIFTT
Heqet Therapeutics is a pre-clinical stage biotech developing non-coding RNA-based therapies for cardiovascular diseases, with a focus on acute myocardial infarction.
BiotechMedical Devices
Mauro Giacca(Founder (Professor of Cardiovascular Sciences))
IAMA Therapeutics develops small-molecule drugs for autism, epilepsies, and other central nervous system disorders, focusing on inhibiting cation-chloride cotransporters to correct atypical brain activity.
BiotechDeep Tech
Co-investorsCDP Venture CapitalIndaco Venture Partners
Kither Biotech is a clinical-stage biotech company developing inhaled cell signal transduction modulators targeting the PI3Kγ signaling axis for respiratory diseases such as COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, and idiopathic pulmonary fibrosis.
BiotechHealthtech
Co-investors3B Future Health FundCDP Venture CapitalElysia CapitalItalian Angels for Growth
Neophore develops a small-molecule therapeutic that transiently inhibits DNA Mismatch Repair (MMR) to convert MMR-proficient tumours into an MMR-deficient state, making them responsive to cancer immunotherapy.
AI & Machine LearningBiotechLongevity
Co-investors3B Future Health FundAstellas Venture Management LLCNeva Sgr.
PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis.
BiotechHealthtech
Nicola Aceto(Co-founder & Chief Science Officer)inChristoph Rochlitz(Co-founder & Chief Medical Officer)inDaniele Scarinci(CEO & Executive Director)inKatharina Venturi(Chief Operating Officer)in
Co-investorsXGEN Venture
Resalis Therapeutics develops antisense oligonucleotide therapies targeting microRNA pathways for metabolic disorders.
BiotechHealthtechLongevityMedical DevicesTurin, IT
Riccardo Panella(Chief Scientific Officer & Co-Founder)inSakari Kauppinen(Chief Technology Officer & Co-Founder)in
Co-investorsItalian Angels for GrowthSunstone Capital
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investors3B Future Health FundCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI Partners+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Arbitro per le Controversie Finanziarie
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.